Uncategorized
FDA grants orphan drug designation to miltefosine for Acanthamoeba keratitis
The FDA has designated miltefosine as an orphan drug for the treatment of Acanthamoeba keratitis, according to a press release from Profunda.Impavido (miltefosine) was licensed by Profunda from Knight Therapeutics in 2015.